Mylan Fails to Stop EpiPen Firestorm as Senators Seek Answers

Updated on
  • Drugmaker will introduce lower-cost generic version of shot
  • 20 senators send letter expressing ‘serious concerns’

Mylan Plans Half-Priced Generic Version of EpiPen

Mylan NV’s latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the sights of Congress.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.